Immunome (IMNM) CEO and director buys shares in public offering

Rhea-AI Filing Summary

Immunome, Inc.'s president and CEO, who is also a director, reported buying additional company stock. On 12/18/2025, the reporting person purchased 46,511 shares of Immunome common stock at a price of $21.5 per share in an open-market style purchase that occurred in connection with the company’s recently completed underwritten public offering of common stock.

Following this transaction, the reporting person beneficially owns 853,247 shares of Immunome common stock held directly. The filing is made on behalf of a single reporting person and reflects a straightforward increase in their direct ownership stake.

Insider Trade Summary

Net Buyer: 46,511 shares

Net Buy 1 txn

Insider SIEGALL CLAY B

Role President and CEO

Bought 46,511 shs ($1000K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	46,511	$21.50	$1000K

Holdings After Transaction: Common Stock — 853,247 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person purchased the shares in connection with the Issuer's recently completed underwritten public offering of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/18/2025 - 05:03 PM Learn about SEC filing dates

FAQ

What insider transaction did Immunome Inc. (IMNM) disclose?

Immunome Inc. disclosed that its president and CEO, who is also a director, purchased 46,511 shares of common stock on 12/18/2025.

At what price were the Immunome (IMNM) shares purchased in this Form 4 filing?

The reporting person bought Immunome common stock at a price of $21.5 per share.

How many Immunome (IMNM) shares does the reporting person own after the reported transaction?

After the transaction, the reporting person beneficially owns 853,247 shares of Immunome common stock directly.

What is the relationship of the reporting person to Immunome Inc. (IMNM)?

The reporting person is both a director and an officer of Immunome Inc., serving as president and CEO.

Was the Immunome (IMNM) insider purchase related to a specific company transaction?

Yes. The filing states that the reporting person purchased the shares in connection with Immunome’s recently completed underwritten public offering of common stock.

Is this Immunome (IMNM) Form 4 filed for one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not a group.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIEGALL CLAY B

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/18/2025		P(1)		46,511	A	$21.5	853,247	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased the shares in connection with the Issuer's recently completed underwritten public offering of common stock.

	/s/ Sandra Stoneman, Attorney-in-Fact	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.